Poseida Therapeutics (NASDAQ:PSTX) Rating Reiterated by HC Wainwright

Poseida Therapeutics (NASDAQ:PSTX)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a research report issued to clients and investors on Wednesday, Benzinga reports. They currently have a $20.00 price target on the stock. HC Wainwright also issued estimates for Poseida Therapeutics’ Q3 2025 earnings at ($0.49) EPS, Q4 2025 earnings at ($0.51) EPS and FY2028 earnings at $0.26 EPS.

Poseida Therapeutics Trading Down 3.6 %

Shares of NASDAQ PSTX opened at $2.95 on Wednesday. Poseida Therapeutics has a 52-week low of $1.54 and a 52-week high of $4.27. The firm’s 50 day moving average price is $2.78 and its 200-day moving average price is $3.02. The company has a debt-to-equity ratio of 0.69, a quick ratio of 2.56 and a current ratio of 2.56. The company has a market cap of $286.03 million, a PE ratio of -2.48 and a beta of 0.46.

Poseida Therapeutics (NASDAQ:PSTX) last released its earnings results on Thursday, March 7th. The company reported ($0.27) EPS for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.09. Poseida Therapeutics had a negative net margin of 131.95% and a negative return on equity of 97.36%. The company had revenue of $25.00 million for the quarter, compared to analysts’ expectations of $12.50 million. On average, equities research analysts expect that Poseida Therapeutics will post -1.66 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Allspring Global Investments Holdings LLC purchased a new position in shares of Poseida Therapeutics in the third quarter worth about $29,000. Bayesian Capital Management LP purchased a new stake in shares of Poseida Therapeutics in the first quarter valued at approximately $33,000. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Poseida Therapeutics during the fourth quarter worth about $36,000. Tower Research Capital LLC TRC raised its holdings in shares of Poseida Therapeutics by 110.5% during the fourth quarter. Tower Research Capital LLC TRC now owns 10,679 shares of the company’s stock valued at $36,000 after acquiring an additional 5,606 shares during the last quarter. Finally, Keystone Financial Group purchased a new position in shares of Poseida Therapeutics in the third quarter worth about $36,000. 46.87% of the stock is currently owned by hedge funds and other institutional investors.

Poseida Therapeutics Company Profile

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.